Two new cell therapies treating leukemia and lymphoma will be reimbursed in Switzerland

Jan 2020

Currently, in Switzerland, two CAR-T cell therapies are approved, both for the treatment of certain types of lymphoma. One of them is also approved for the treatment of certain forms of leukemia. The Swiss Federal Department for Home Affairs (FDHA) has decided to regulate their reimbursement of these treatments in the Services Ordinance (KLV/OPre) in more detail in January 2020. The reimbursement under the compulsory health care insurance applies only under certain conditions and is currently limited until the end of 2022. Until then, the efficacy, appropriateness and cost-effectiveness (EAE criteria) of the two therapies must be ascertained by the data.

The services can be delivered in centers that already carry out bone marrow transplants and have the corresponding accreditation.

Since these treatments are inpatient benefits, they will be reimbursed within the framework of Swiss DRG. The amount of the reimbursement can be found in the SwissDRG 9.0 (2020/2020) tariff version.

See the news here.

In addition to these changes, a number of other adjustments have been made to the OPre/KLV and its annexes. All changes to OPre/KLV entered into force on January 1, 2020.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

Matrix-associated autologous chondrocyte implantation on the knee joint reimbursed in Germany

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

2022 RIHN and Supplementary list for IVD tests published in France

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

New procedure and diagnostic codes added to the private reimbursement schedule in England

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Theme survey on products for monitoring and diagnostics of sepsis launched by Swedish TLV

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Healthcare Implementation Communique updated in Turkey

Mar 2022

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.